Sanctuary Advisors’s Charles River Laboratories CRL Stock Holding History

Sanctuary Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.34M	Buy	5,903 +1,862	+46%	+$332K	0.01%	1285
2026 Q1	$697K	Sell	4,041 -1,810	-31%	-$336K	﹤0.01%	1558
2025 Q4	$1.17M	Sell	5,851 -394	-6%	-$71.5K	0.01%	1244
2025 Q3	$977K	Sell	6,245 -82	-1%	-$13K	0.01%	1303
2025 Q2	$960K	Sell	6,327 -10,001	-61%	-$1.33M	0.01%	1243
2025 Q1	$2.46M	Sell	16,328 -855	-5%	-$143K	0.02%	712
2024 Q4	$2.85M	Sell	17,183 -196	-1%	-$37.8K	0.02%	721
2024 Q3	$3.4M	Sell	17,379 -6,293	-27%	-$1.31M	0.02%	658
2024 Q2	$5.42M	Buy	+23,672	New	+$5.36M	0.04%	427

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Sanctuary Advisors's CRL Position: Q2 2026 in Review

Sanctuary Advisors increased its Charles River Laboratories (CRL) stake by 46% in Q2 2026, buying an estimated $332K and bringing the position to 5,903 shares worth $1.34M. The position accounts for 0.01% of the portfolio, ranked #1285.

Sanctuary Advisors first reported a position in CRL in Q2 2024 and has held it in 9 quarters since. The position peaked at $5.42M in Q2 2024. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Sanctuary Advisors held 5,903 shares of Charles River Laboratories worth $1.34M as of Q2 2026.
Sanctuary Advisors bought 1,862 Charles River Laboratories shares in Q2 2026, an estimated $332K.
Charles River Laboratories made up 0.01% of Sanctuary Advisors's portfolio in Q2 2026, its #1285 holding.
Sanctuary Advisors first reported a position in Charles River Laboratories in Q2 2024 and has held it in 9 quarters since.
Sanctuary Advisors's Charles River Laboratories position peaked at $5.42M in Q2 2024.
568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Sanctuary Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.